InVivo Therapeutics Holdings Corp (NVIVQ)

[attilathehunt]

If I read the 10Q correctly...16 patients, 2 died (no fault to NSS). Of the 14, 8 passed six months (5 improvements), 2 reverted back to AIS A prior to six month evaluation. I assume the one who never improved was patient #2. The remaining six, have not reached their 6 month evaluation. So it looks like we need 6 more enrollments to have at least 20 evaluable patients.

Expect enrollment to end in Q3 of this year., with HDE submission in early 2018 ( must likely not until April assuming #20 is enrolled by Sept 30, 2017).

Assuming no more improvements, worse case we would be at 25% (5 out of 20). Best case 55% ( the current 5 + the next 6 /20).

Best of luck.